Prentiss Smith & CO Inc Neurocrine Biosciences Inc Transaction History
Prentiss Smith & CO Inc
- $144 Million
- Q4 2024
A detailed history of Prentiss Smith & CO Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Prentiss Smith & CO Inc holds 4,763 shares of NBIX stock, worth $545,268. This represents 0.45% of its overall portfolio holdings.
Number of Shares
4,763Holding current value
$545,268% of portfolio
0.45%Shares
1 transactions
Others Institutions Holding NBIX
# of Institutions
656Shares Held
96.6MCall Options Held
282KPut Options Held
281K-
Black Rock Inc. New York, NY14.2MShares$1.62 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.16 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$560 Million0.03% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$345 Million0.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$291 Million0.06% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $10.9B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...